ASCO: Lilly seeks prostate cancer redemption after Verzenio flop

After two recent back-to-back trial flops, Eli Lilly doesn't plan to develop Verzenio further in prostate cancer.

Related Keywords

United States ,American ,Johnson ,Novarti Pluvicto ,Eli Lilly ,Novartis ,American Society Of Clinical Oncology ,Astrazeneca ,American Society ,Clinical Oncology ,